The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib

The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant, improving outcome for patients with refractory chronic myeloid leukemia (CML). However, responses are variable, and causal b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Parker, Wendy T., Yeung, David T. O., Yeoman, Alexandra L., Altamura, Haley K., Jamison, Bronte A., Field, Chani R., Hodgson, J. Graeme, Lustgarten, Stephanie, Rivera, Victor M., Hughes, Timothy P., Branford, Susan
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2016
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4832506/
https://ncbi.nlm.nih.gov/pubmed/26773037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-09-666214
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados